Hot Features
Premium
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Hemogenyx Pharmaceuticals plc (LSE:HEMO) has announced the successful treatment of a second patient in its Phase I clinical trial of HG-CT-1, a CAR-T cell therapy targeting relapsed or refractory acute myeloid leukemia (AML) in adults. This important milestone highlights the ongoing advancement of HG-CT-1 in clinical development and reinforces the potential of this innovative therapy to offer new hope for patients with limited treatment options.
The trial is designed to position HG-CT-1 as a leading therapeutic option for hematologic malignancies, with plans for future pediatric trials to address significant unmet needs in AML. Hemogenyx is optimistic that this program will deliver substantial long-term value for patients and shareholders alike.
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a biopharmaceutical company based in London, with US operations in New York City. The company specializes in the development of novel treatments for blood disorders and autoimmune diseases. Leveraging its unique product candidates and platform technologies, Hemogenyx is committed to pioneering new therapies with the potential to transform patient care in these critical areas.
-
Year-to-Date Share Performance: -55.12%
-
Average Daily Trading Volume: 36,948 shares
-
Technical Sentiment Indicator: Buy
-
Market Capitalization: £7.44 million
